Literature DB >> 10749587

Serum levels of the soluble adhesion molecules in patients with malignant melanoma.

V Yasasever1, F Tas, D Duranyildiz, H Camlica, S Kurul, N Dalay.   

Abstract

The incidence of malignant melanoma has been steadily increasing over the past decades. CD 44 is a transmembrane glycoprotein which is implicated in a number of adhesive and migratory events. Downregulation of CD 44 is implicated in the metastatic process. P-Selectin is a member of the selectin family of cell surface molecules. The levels of P-Selectin in biological fluids may be elevated in subjects with a variety of pathological conditions. In malignant melanoma, elevation of the plasma level of soluble intercellular adhesion molecule-1 (sICAM-1) has been associated with a reduction in disease-free survival. This study was performed to investigate the differences in the serum concentrations of the adhesion molecules in patients with malignant melanoma. The study group consisted of 52 patients with malignant melanoma and 20 healthy subjects. No meaningful difference was observed for P-selectin and sICAM 1 levels. A statistically significant decrease was observed in the cancer patients for serum CD 44 levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749587     DOI: 10.1007/bf03032657

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  21 in total

1.  Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma.

Authors:  M Altomonte; F Colizzi; G Esposito; M Maio
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

2.  Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling.

Authors:  K Ley; T F Tedder
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

3.  Endothelial CD44H mediates adhesion of a melanoma cell line to quiescent human endothelial cells in vitro.

Authors:  E A Price; D R Coombe; J C Murray
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

4.  Enhancement of natural killer activity by an antibody to CD44.

Authors:  P H Tan; E B Santos; H C Rossbach; B M Sandmaier
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

5.  Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis.

Authors:  B F Haynes; L P Hale; K L Patton; M E Martin; R M McCallum
Journal:  Arthritis Rheum       Date:  1991-11

Review 6.  The selectins: vascular adhesion molecules.

Authors:  T F Tedder; D A Steeber; A Chen; P Engel
Journal:  FASEB J       Date:  1995-07       Impact factor: 5.191

7.  Soluble intercellular adhesion molecule 1 (sICAM-1) and malignant melanoma.

Authors:  J Viac; A Gueniche; M Faure; A Claudy
Journal:  Cancer Lett       Date:  1993-08-31       Impact factor: 8.679

8.  Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.

Authors:  D Schadendorf; S Diehl; T Zuberbier; C Schadendorf; B M Henz
Journal:  Dermatology       Date:  1996       Impact factor: 5.366

Review 9.  Cell adhesion receptor expression during melanoma progression and metastasis.

Authors:  I R Hart; M Birch; J F Marshall
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

10.  Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer.

Authors:  G Sliutz; C Tempfer; S Winkler; P Kohlberger; A Reinthaller; C Kainz
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more
  2 in total

1.  Proteoglycans in Normal and Healing Skin.

Authors:  Margaret Mary Smith; James Melrose
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

2.  The clinical usefulness of assessing the concentration of cell adhesion molecules sVCAM-1 and sICAM-1 in the serum of women with primary breast cancer.

Authors:  Anna Thielemann; Aleksandra Baszczuk; Zygmunt Kopczyński; Adrianna Nowak; Sylwia Grodecka-Gazdecka
Journal:  Contemp Oncol (Pozn)       Date:  2014-08-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.